By Denny Jacob
Corvus Pharmaceuticals shares jumped 29% in premarket trading after new interim data in a study evaluating soquelitinib.
Shares were trading around $4.33. The stock is down 38% on the year.
The clinical-stage biopharmaceutical company said Thursday that new data from a Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis demonstrated a favorable safety and efficacy profile.
Overall, three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints, said Corvus.
The company said it's on track to initiate a Phase 2 trial before the end of the year.
Soquelitinib is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function, according to Corvus.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 09, 2025 08:35 ET (12:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。